BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia

Abstract EVI1-rearranged acute myeloid leukemia (AML) with inv(3)(q21q26) or t(3;3)(q21q26) represents a distinct and aggressive subtype characterized by poor prognosis and limited treatment options. However, the optimal strategy to overcome resistance to conventional therapy remains elusive. Buildi...

Full description

Bibliographic Details

Main Authors:	Weijia Zang, Yui Koike, Koutarou Nishimura, Atsushi Tanaka, Hiromi Yamazaki, Takaya Yamasaki, Hiromi Ito, Yifan Zhang, Yumi Aoyama, Wataru Saika, Muran Xiao, Chihiro Hasegawa, Hiroyoshi Kunimoto, Hideaki Nakajima, Fumihiko Ishikawa, Akifumi Takaori-Kondo, Daichi Inoue
Format:	Artigo
Language:	Inglês
Published:	Nature Portfolio 2025-10-01
Series:	Scientific Reports
Subjects:	Acute myeloid leukemia EVI1 Venetoclax Hypomethylating agent MYB BRD4
Online Access:	https://doi.org/10.1038/s41598-025-21034-1
Tags:	Add Tag No Tags, Be the first to tag this record!